These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 20461787)

  • 1. Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies.
    Farragher TM; Lunt M; Plant D; Bunn DK; Barton A; Symmons DP
    Arthritis Care Res (Hoboken); 2010 May; 62(5):664-75. PubMed ID: 20461787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register.
    Bukhari M; Thomson W; Naseem H; Bunn D; Silman A; Symmons D; Barton A
    Arthritis Rheum; 2007 Sep; 56(9):2929-35. PubMed ID: 17763407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis.
    Burr ML; Viatte S; Bukhari M; Plant D; Symmons DP; Thomson W; Barton A
    Arthritis Res Ther; 2012 May; 14(3):R109. PubMed ID: 22571727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeated anticitrullinated protein antibody and rheumatoid factor assessment is not necessary in early arthritis: results from the ESPOIR cohort.
    Gossec L; Paternotte S; Combe B; Meyer O; Dougados M
    J Rheumatol; 2014 Jan; 41(1):41-6. PubMed ID: 24241481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of third generation anti-CCP antibodies in the diagnosis of rheumatoid arthritis from undifferentiated polyarthritis after 4 years of follow-up.
    Caro-Oleas JL; Fernández-Suárez A; Reneses Cesteros S; Porrino C; Núñez-Roldán A; Wichmann Schlipf I
    Clin Exp Rheumatol; 2008; 26(3):461-3. PubMed ID: 18578970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
    Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
    J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset.
    Berglin E; Johansson T; Sundin U; Jidell E; Wadell G; Hallmans G; Rantapää-Dahlqvist S
    Ann Rheum Dis; 2006 Apr; 65(4):453-8. PubMed ID: 16176994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
    Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
    Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-MCV antibodies predict radiographic progression in Greek patients with very early (<3 months duration) rheumatoid arthritis.
    Barouta G; Katsiari CG; Alexiou I; Liaskos C; Varna A; Bogdanos DP; Germenis AE; Sakkas LI
    Clin Rheumatol; 2017 Apr; 36(4):885-894. PubMed ID: 27943044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of anticyclic citrullinated peptide antibodies and/or rheumatoid factor status and clinical presentation in early arthritis: results from the ESPOIR cohort.
    Mouterde G; Lukas C; Goupille P; Flipo RM; Rincheval N; Daurès JP; Combe B
    J Rheumatol; 2014 Aug; 41(8):1614-22. PubMed ID: 25028372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis.
    Potter C; Hyrich KL; Tracey A; Lunt M; Plant D; Symmons DP; Thomson W; Worthington J; Emery P; Morgan AW; Wilson AG; Isaacs J; Barton A;
    Ann Rheum Dis; 2009 Jan; 68(1):69-74. PubMed ID: 18375541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritis.
    Mjaavatten MD; van der Heijde D; Uhlig T; Haugen AJ; Nygaard H; Sidenvall G; Helgetveit K; Kvien TK
    Arthritis Res Ther; 2010; 12(3):R76. PubMed ID: 20444271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.
    Bruns A; Nicaise-Roland P; Hayem G; Palazzo E; Dieudé P; Grootenboer-Mignot S; Chollet-Martin S; Meyer O
    Joint Bone Spine; 2009 May; 76(3):248-53. PubMed ID: 19208451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes in recent-onset inflammatory polyarthritis differ according to initial titers, persistence over time, and specificity of the autoantibodies.
    Guzian MC; Carrier N; Cossette P; de Brum-Fernandes AJ; Liang P; Ménard HA; Boire G
    Arthritis Care Res (Hoboken); 2010 Nov; 62(11):1624-32. PubMed ID: 20617532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis.
    Jansen AL; van der Horst-Bruinsma I; van Schaardenburg D; van de Stadt RJ; de Koning MH; Dijkmans BA
    J Rheumatol; 2002 Oct; 29(10):2074-6. PubMed ID: 12375314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance of anti-cyclic citrullinated peptide and rheumatoid factor in patients with rheumatoid arthritis.
    Chang PY; Yang CT; Cheng CH; Yu KH
    Int J Rheum Dis; 2016 Sep; 19(9):880-6. PubMed ID: 25940989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Predictive values of anti-cyclic citrullinated peptide antibody, antikeratin antibody and rheumatoid factor in diagnosing articular erosions in patients with rheumatoid arthritis].
    Xie QB; Yin G
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):508-12. PubMed ID: 19627016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis.
    Ateş A; Karaaslan Y; Aksaray S
    Clin Rheumatol; 2007 Apr; 26(4):499-504. PubMed ID: 16670828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticyclic citrullinated peptide antibody and rheumatoid factor in south Tunisian patients with rheumatoid arthritis: association with disease activity and severity.
    Hamad MB; Marzouk S; Kaddour N; Masmoudi H; Fakhfakh F; Rebai A; Bahloul Z; Maalej A
    J Clin Lab Anal; 2014 Jan; 28(1):21-6. PubMed ID: 24375820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.